Evolving landscape in castration-resistant prostate cancer

Bookmark and Share
Published: 21 Oct 2011
Views: 3898
Rating:
Save
Dr Per-Anders Abrahamsson - Lund University, Sweden; Dr Chris Parker - Royal Marsden Cancer Center, London, UK
A review of data and expert opinion from European Multidisciplinary Cancer Congress (EMCC) 2011: Dr Chris Parker and Dr Per-Anders Abrahamsson discuss the release of information on three new drugs designed to fight against casteration resistant prostate cancer. The three drugs Sipuleucel-t provenge, Cabazitaxel and abiraterone are very exciting news has little in the way of progress has been made to fight this type of cancer. Dr Parker and Dr Per-Anders Abrahamsson discuss the potential of each drug and the timeline for trials.